구독하기
연구 모델
서비스
전임상 효능 평가
Resource
huDR3(TNFRSF25) Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huDR3(TNFRSF25) Mouse
제품명
huDR3(TNFRSF25) Mouse
제품 ID
C002066
품종 계통
C57BL/6NCya-Tnfrsf25tm1(hTNFRSF25)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huDR3(TNFRSF25) Mouse (카탈로그 번호 C002066)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
기본 정보
관련 자료
기본 정보
유전자명
유전자 별칭
DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, GEF720, WSL-LR, PLEKHG5, TNFRSF12
NCBI ID
염색체
Chr 1
MGI ID
Datasheet
품종 계통 설명
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25), also known as death receptor 3 (DR3), is a member of the tumor necrosis factor receptor (TNFR) superfamily and serves as the specific receptor for TNFSF15 (TL1A). It plays a critical role in immune homeostasis regulation, inflammatory responses, and apoptosis. This receptor contains a death domain and can specifically bind to its ligand TL1A. Upon binding, it recruits downstream adaptor molecules to activate NF-κB and MAPK signaling pathways, or induce apoptosis, thereby participating in the regulation of T cell proliferation and differentiation—particularly Th2 and Th17 cells—regulatory T cell (Treg) expansion, and tissue inflammatory responses [1]. TNFRSF25 is primarily expressed in lymphocyte-rich tissues, such as the spleen, thymus, and lymph nodes. It is highly expressed on the surface of activated T cells, NKT cells, and certain innate lymphoid cells, and can also be detected in mucosal tissues such as the intestine and lungs, suggesting its important role in mucosal immunity and inflammation regulation [2].
Abnormal activation of the TNFRSF25/TL1A signaling pathway is closely associated with the development of various inflammatory and autoimmune diseases, with particularly prominent roles in inflammatory bowel disease (IBD), allergic asthma, and psoriasis. Studies have shown that in inflammatory bowel disease, TNFRSF25 signaling promotes Th17 cell activation and amplifies intestinal inflammation, and is also involved in fibrosis processes. In allergic asthma, this pathway enhances Th2-type immune responses and airway inflammation [1,3]. Based on its critical role in immune regulation, TNFRSF25 has become a highly promising therapeutic target in the field of immunotherapy for inflammatory and autoimmune diseases. Anti-TL1A monoclonal antibodies have demonstrated favorable efficacy in clinical trials for IBD [4-5].
huDR3(TNFRSF25) mice are humanized models constructed using gene editing technology. In this model, the sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene. huDR3(TNFRSF25) mice can be used for preclinical studies on the pathogenesis of autoimmune and inflammatory diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis, as well as for the evaluation of DR3-targeted drugs.
Reference
Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 2008;205(5):1037-1048.
Meylan F, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4(2):172-185.
Clarke AW, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10(5):664-677.
Sands BE, et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024.
Feagan BG, et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol. 2025.
변형 전략
The sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene.

Figure 1. Gene editing strategy of huDR3(TNFRSF25) mice.
응용 분야
The screening, development, and preclinical evaluation of TNFRSF25-targeted drugs;
Research on the pathogenesis and treatment of autoimmune diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis;
Research on the mechanism of the TNFRSF25/TL1A signaling pathway.
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
